CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

CareDx reports robust Q4 earnings, eyes revenue growth opportunities

CareDx's Q4 2024 performance reflects strong revenue growth, profitability, and cash position, setting a positive trajectory for future growth. The company's strategic focus on expanding payer coverage, partnerships, and market presence positions it well for achieving its revenue targets. While facing challenges in maintaining growth and profitability, CareDx has opportunities to capitalize on market expansion and operational enhancements for sustained success.

CareDx reports strong Q1 earnings, poised for growth opportunities

CareDx demonstrated robust financial performance and operational efficiency in Q1 2025, supported by revenue growth, margin expansion, and strategic market expansions. While facing challenges in maintaining growth and navigating market complexities, the company's strong balance sheet and innovative product offerings position it well for future opportunities. By leveraging its strengths in innovation, market expansion, and financial stability, CareDx is poised to capitalize on opportunities for growth and visibility in the transplant care market.

CareDx reports robust Q2 earnings, unveils AI diagnostics at WTC

CareDx delivered strong financial performance in Q2 2025, showcasing revenue growth and profitability, while also demonstrating leadership in transplant diagnostics and innovation. Despite challenges like leadership transitions and market competition, the company's strategic strengths in product development and market presence position it well for future growth. By leveraging opportunities in expanding its product offerings, addressing market needs, and maintaining growth momentum, CareDx is poised to navigate challenges and drive continued success.

CareDx reports robust Q3 earnings, advances in transplant diagnostics

CareDx delivered impressive financial results in Q3 2025, showcasing strong revenue growth and operational improvements. The company's focus on innovation, product validation, and strategic initiatives positions it well for future success in the transplant diagnostics market. While facing challenges in a competitive landscape and regulatory environment, CareDx has opportunities to drive growth through market expansion and technological advancements. Overall, CareDx's Q3 performance reflects a solid foundation for continued growth and leadership in the healthcare industry.